Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2007; 13(30): 4100-4102
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4100
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4100
Table 1 Results of endoscopic findings
| Parameters | Baseline (d 0) | After therapy (d 28) | Analysis of findings | ||||||
| Dexrabeprazole 10 mg(n = 25) | Rabeprazole 20 mg(n = 25) | Dexrabeprazole10 mg (n = 25) | Rabeprazole20 mg (n = 25) | CER | TER | ARR | RRR | NNT | |
| Patients with esophagitis[4] | 21 | 23 | 8 | 15 | 0.65 | 0.38 | 0.27 | 42% | 4 |
| Grade A | 1 | 7 | 8 | 11 | |||||
| Grade B | 20 | 16 | 0 | 4 | |||||
| Grade C | 0 | 0 | 0 | 0 | |||||
| Grade D | 0 | 0 | 0 | 0 | |||||
| Investigator-reported improvement in endoscopic findings and healing | |||||||||
| -Yes | NA | NA | 20 | 15 | 0.652 | 0.952 | 0.30 | 46% | 3 |
| -No | NA | NA | 1 | 8 | |||||
-
Citation: Pai V, Pai N. Randomized, double-blind, comparative study of dexrabeprazole 10 mg
versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease. World J Gastroenterol 2007; 13(30): 4100-4102 - URL: https://www.wjgnet.com/1007-9327/full/v13/i30/4100.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i30.4100